


In the claims:

1. (Currently Amended) An amide derivative represented by the following formula [1] in any of the following cases (A) or (B), or a salt thereof;




(A)

R¹ represents a saturated cyclic amino group (the saturated cyclic amino group may be substituted by 1 to 3 same or different members selected from the group consisting of alkyl, alkoxy carbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl), monoalkylamino or dialkylamino;

R² represents alkyl, halogen, haloalkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxy carbonyl, acyl, amino, monoalkylamino, dialkylamino, nitro, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl or cyano;

R³ represents hydrogen, halogen or alkoxy;

Het1 represents any of groups of the following formulas [2] to [8];



Het2 represents pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl or 1, 2-dihydropyridazinyl (the Het2 may be substituted by 1 to 3 same or different members selected from the group consisting of alkyl, halogen and amino);

Excluding compound wherein R^1 is (i) pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl, all of which may be substituted by 1 to 3 same or different members selected from the group consisting of alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl, (ii) monoalkylamino, or (iii) dialkylamino, Het1 is a group of the formula [6], and Het2 is pyrazinyl or pyridyl which may be substituted by alkyl;

(B)

R^1 represents ~~4-methylpiperazin-1-yl, 1-pyrrolidinyl, piperidino, 4-ethylpiperazin-1-yl, 4-n-propylpiperazin-1-yl, cis-3, 5-dimethylpiperazin-1-yl, morpholino, dimethylamino or diethylamino;~~

~~R² represents methyl, halogen, trifluoromethyl, methoxy, methoxycarbonyl, nitro, dimethylcarbamoyl or cyano;~~

~~R³ represents hydrogen, bromo or methoxy;~~

~~Het1 represents a group of the formula [6]; and~~

~~Het2 represents 3-pyridyl.~~

2. (Original) The amide derivative according to claim 1, or a salt thereof, wherein R¹ is a saturated cyclic amino group (the saturated cyclic amino group may be substituted by 1 to 3 same or different members selected from the group consisting of alkyl and alkoxycarbonyl), monoalkylamino or dialkylamino,

R² is alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, nitro, dialkylcarbamoyl or cyano,

R² is hydrogen, halogen or alkoxy,

Het1 is any of groups of the formulas [2] to [8], and

Het2 is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl or 1, 2-dihydropyridazinyl (the Het2 may be substituted by 1 to 3 same or different halogen).

3. (Currently Amended) The amide derivative according to claim 1, which is a compound selected from the group consisting of the following compounds (1) to (40 ~~18~~), or a salt thereof:

(1) ~~3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-~~

~~(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide~~

(2) ~~3-iodo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide,~~

(3) ~~3-chloro-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide,~~

(4) ~~3-fluoro-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide,~~

- (5) ~~4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide,~~
- (6 1) 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide,
- (7) ~~3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(2-pyrazinyl)pyrimidin-2-ylamino]phenyl}benzamide,~~
- (8 2) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{3-[4-(6-chloropyridin-3-yl)pyrimidin-2-ylamino]-4-methylphenyl}benzamide,
- (9 3) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-methylphenyl}benzamide,
- (10 4) 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-methylphenyl}benzamide,
- (11 5) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{3-[4-(1,2-dihydropyridazin-4-yl)pyrimidin-2-ylamino]-4-methylphenyl}benzamide,
- (12 6) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridazinyl)pyrimidin-2-ylamino]phenyl}benzamide,
- (13 7) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide,
- (14 8) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyridin-2-ylamino]phenyl}benzamide.
- (15 9) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyridin-2-ylamino]phenyl}benzamide.

~~(16 10)~~ 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[2-(3-pyridyl) pyridin-6-ylamino] phenyl} benzamide,

~~(17 11)~~ 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[3-(3-pyridyl) pyridin-5-ylamino] phenyl} benzamide,

~~(18 12)~~ 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[3-(3-pyridyl) phenylamino] phenyl } benzamide,

~~(19 13)~~ 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[2-(3-pyridyl) pyrazin-6-ylamino] phenyl} benzamide,

~~(20 14)~~ 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[5-(3-pyridyl)-1, 2, 4-triazin-3-ylamino] phenyl} benzamide,

~~(21)~~ 3-methyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl} benzamide,

~~(22)~~ 4-(4-methylpiperazin-1-ylmethyl)-3-nitro-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl} benzamide,

~~(23)~~ 3-methoxy-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl} benzamide,

~~(24)~~ 3,5-dibromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl} benzamide,

~~(25)~~ 3,5-dimethoxy-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl} benzamide,

~~(26)~~ 3-(N,N-dimethylcarbamoyl)-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl} benzamide,

- (27) ~~3-bromo-4-(4-ethylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide,~~
- (28) ~~3-bromo-4-[4-(n-propyl)piperazin-1-ylmethyl]-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide,~~
- (29) ~~3-bromo-4-(N,N-dimethylaminomethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide,~~
- (30) ~~3-bromo-4-(N,N-diethylaminomethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide,~~
- (31) ~~3-bromo-4-(1-pyrrolidinylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide,~~
- (32) ~~3-bromo-4-(piperidinomethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide,~~
- (33) ~~3-bromo-4-(morpholinomethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide,~~
- (34) ~~3-bromo-4-(cis-3,5-dimethylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide,~~
- (35 15) 3-bromo-4-(4-methyl-hexahydro-1H-1,4-diazepin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide,
- (36 16) 3-bromo-4-(1-piperazinylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide,
- (37 17) 4-[4-(t-butoxycarbonyl)piperazin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, and

(38 ~~18~~)4-(1-piperazinylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl) pyrimidin-2-ylamino]phenyl } benzamide;

(39) ~~3 methoxycarbonyl 4 (4-methylpiperazin-1-ylmethyl) N {4-methyl-3-[4 (3-pyridyl) pyrimidin-2-ylamino] phenyl} benzamide, and~~

(40) ~~3-cyano 4 (4-methylpiperazin-1-ylmethyl) N { 4-methyl-3-[4 (3-pyridyl) pyrimidin-2-ylamino] phenyl} benzamide.~~

4. (Previously Presented) A pharmaceutical composition comprising the amide derivative of claim 1 or a salt thereof as an active ingredient and a pharmaceutically acceptable carrier.

5. - 8. (Cancelled)

9. (Previously Presented) A method of treating a subject having acute lymphoblastic leukemia comprising administering to the subject an effective amount of the amide derivative of claim 1 or a salt thereof.

10. (Previously Presented) A method of treating a subject having acute myelogenous leukemia comprising administering to the subject an effective amount of the amide derivative of claim 1 or a salt thereof.

11. (Previously Presented) A method of treating a subject having acute myelogenous leukemia comprising administering to the subject an effective amount of the amide derivative of claim 1 or a salt thereof.